Amryt’s epidermolysis bullosa trial extended
Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years.
Read More
Tag: IDMC
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
